![]() | |
![]() | |
![]() | |
Names | |
---|---|
Preferred IUPAC name 2-Phenyl-1,2-benzoselenazol-3(2H)-one | |
Identifiers | |
3D model (JSmol) | |
ChEBI | |
ChEMBL | |
ChemSpider | |
ECHA InfoCard | 100.132.190 |
PubChem CID | |
UNII | |
CompTox Dashboard (EPA) | |
| |
| |
Properties | |
C13H9NOSe | |
Molar mass | 274.17666 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). |
Ebselen (also called PZ 51, DR3305, and SPI-1005), is a synthetic organoselenium molecule under preliminary investigation as a drug candidate. [1] It belongs to the class of compounds related to benzene and its derivatives. [1] It is being developed by the Seattle biotechnology company, Sound Pharmaceuticals, Inc. [1] It has also been reported to target tubulin, blocking its polymerization. [2]
Ebselen has been entered into clinical trials as a lead compound intended for the potential treatment of various diseases. [3] Its most advanced clinical trial is a Phase III study in people with Meniere's disease, completed in July 2024. [4]
In vitro, ebselen is a mimic of glutathione peroxidase and reacts with peroxynitrite. [5] It is purported to have antioxidant and anti-inflammatory properties. [1] [5]
Generally, synthesis of the characteristic scaffold of ebselen, the benzoisoselenazolone ring system, can be achieved either through reaction of primary amines (RNH2) with 2-(chloroseleno)benzoyl chloride (Route I), [6] by ortho-lithiation of benzanilides followed by oxidative cyclization (Route II) mediated by cupric bromide (CuBr2), [7] or through the efficient Cu-catalyzed selenation / heterocyclization of o-halobenzamides, a methodology developed by Kumar et al. [8] (Route III).
The first patent for 2-phenyl-1,2-benzoselenazol-3(2H)-one was filed in 1980 and granted in 1982. [9]
Ebselen is in preliminary clinical development for the potential treatment of hearing loss and depression, among other medical indications. [3] [10]